Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Eye disorders – page 6

  • 373 clinical trials
  • 123 recruiting
  • 138 conditions
  • 27 countries

Conditions in this area

138 conditions with trials, the busiest first

Conjunctivitis allergic34Sjogren's syndrome31Endocrine ophthalmopathy26Neovascular age-related macular degeneration23Giant cell arteritis18Seasonal allergy17Uveal melanoma17Dry age-related macular degeneration16Rhinitis allergic16Diabetic retinal oedema13Dry eye12Age-related macular degeneration11Retinitis pigmentosa11Asthma10Graves' disease10Myopia10Glaucoma8Open angle glaucoma8Uveitis8Immunoglobulin G4 related disease7Behcet's syndrome6Cataract6Mite allergy6Neuromyelitis optica spectrum disorder6+114

Clinical trials in Eye disorders

373 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

373 clinical trials

Conjunctivitis allergic+3

Recruiting

Study on the Effectiveness and Safety of Mannan-Conjugated Allergoids for Treating Allergic Rhinitis/Rhinoconjunctivitis in Patients Allergic to House Dust Mites

Investigational
Countries:PortugalPortugal
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Dermatophagoides pteronyssinus enriched allergoid, mannan-conjugated, polymerised
  • Sponsor:Inmunotek S.L.

Leber's congenital amaurosis

Recruiting

Study on the Effectiveness and Safety of Sepofarsen for Patients with Leber Congenital Amaurosis Due to a Specific Genetic Mutation

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Sepofarsen
  • Sponsor:Laboratoires Thea

Dry age-related macular degeneration

Recruiting

Study on the Effectiveness and Safety of GAL-101 Eye Drops for Patients with Geographic Atrophy from Age-Related Macular Degeneration

Investigational
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:SODIUM (R)-2-(2-AMINO-3-(1H-INDOL-3- YL)PROPANAMIDO)-2-METHYLPROPANOATE-PROPAN-2-OL
  • Sponsor:Galimedix Therapeutics Inc.

Age-related macular degeneration

Recruiting

Study on Treating Neovascular Age-Related Macular Degeneration with Aflibercept, Ranibizumab, and Brolucizumab for Patients with Active Disease

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept
  • Sponsor:Medical University Of Vienna

Pterygium

Recruiting

Study on Fibrin Matrix and Autologous Growth Factor Eye Drops for Pterygium Surgery Patients

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years
  • Sponsor:Fundacio Institut De Recerca De L Hospital De La Santa Creu I Sant Pau

Dry age-related macular degeneration+1

Recruiting

Study of Pozelimab and Cemdisiran for Adults with Geographic Atrophy from Age-Related Macular Degeneration

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Cemdisiran
  • Sponsor:Regeneron Pharmaceuticals Inc.

Uveal melanoma+1

Recruiting

Study of Roginolisib for Patients with Advanced Uveal Melanoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Dacarbazine Citrate
  • Sponsor:iOnctura SA

Central serous chorioretinopathy

Recruiting

Study on the Effects of Prednisolone Acetate and Placebo Eye Drops for Patients with Chronic Central Serous Chorioretinopathy

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Dextran 70
  • Sponsor:Stichting Radboud universitair medisch centrum

Basal cell naevus syndrome

Recruiting

Study of Sonidegib for Patients with Nevoid Basal Cell Carcinoma Syndrome and Sporadic Basal Cell Carcinoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Sonidegib
  • Sponsor:Fondazione GONO Plus

Glaucoma+1

Recruiting

Study on the Effectiveness of PRGF Eye Drops for Treating Dry Eye in Glaucoma Patients

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Platelet Concentrate
  • Sponsor:Biotechnology Institute I Mas D S.L.

Autoimmune uveitis

Recruiting

Study on the Effects of Escherichia coli Nissle 1917 in Patients with Autoimmune Uveitis

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years
  • Substances:Escherichia coli strain Nissle 1917
  • Sponsor:Vseobecna Fakultni Nemocnice V Praze

Substances studied in this area

The therapies tested most often in Eye disorders trials.

Aflibercept27 clinical trialsSodium Chloride16 clinical trialsPrednisone14 clinical trialsRanibizumab14 clinical trialsDexamethasone11 clinical trialsDexamethasone Phosphate10 clinical trialsFluorescein Sodium10 clinical trialsPrednisolone10 clinical trialsNivolumab8 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.